All I can say is: “No $%@#, Sherlock” when I read articles like some of the ones I’ve read recently about the status of hemophilia A and hemophilia B treatments.
And it’s making me laugh because it doesn’t take a rocket scientist to figure out that patients—people who are living with hemophilia are becoming empowered! They are making decisions about their treatment options sometimes before consulting with their doctors. They are asking for specific treatments, options. They want to take control. And more power to ‘em!
As you may know, a great deal of effort has recently been spent to analyze treatment options and actually how healthcare options are changing the ever-changing landscape of drugs.
To help bring this to light, key experts in the field of healthcare and pharma got together and analyzed a significant amount of data and here are some of the highlights:
- Coverage for Patients – data shows that access for treatments to manage hemophilia are expensive and restrictive based on averages. It’s also very common to require authorizations by healthcare professionals and require interventions. It’s not always easy and accessible.
- Drug Products and Treatments – commercial pharmacies are the least restrictive, while the greatest restrictions were seen with various health exchange pharmacies and specialty pharmacies.
- Medicare – offered approximately the same amount of access, but at the same time, a larger percentage of available treatments were not covered.
- Biggest Change – Pharmaceutical and biotechnology companies are discovering that there is a significant increase in patients – consumers driving the request for treatment options. Patients are becoming more informed about their options and specifically requesting certain treatments. Direct-to-patient pharmaceutical marketing is on the rise.
For more information, you can read the full article here.
